-+ 0.00%
-+ 0.00%
-+ 0.00%

TG Therapeutics presents Phase 4 ENABLE real-world BRIUMVI data at AAN meeting

PUBT·04/22/2026 11:33:31
Listen to the news
TG Therapeutics presents Phase 4 ENABLE real-world BRIUMVI data at AAN meeting
  • TG Therapeutics announced upcoming data presentations on BRIUMVI (ublituximab-xiiy) in relapsing forms of multiple sclerosis at American Academy of Neurology 2026 annual meeting in Chicago.
  • ENABLE Phase 4 observational study results will be presented, highlighting real-world treatment experience for patients starting BRIUMVI.
  • ENHANCE study updates will be presented, indicating a modified IV dosing approach showed safety and tolerability consistent with continued use.
  • Release positioned presentations as further support for BRIUMVI differentiation in effectiveness, safety, tolerability, with potential to strengthen commercial adoption in adult RMS.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TG Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604220730PRIMZONEFULLFEED9694693) on April 22, 2026, and is solely responsible for the information contained therein.